Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA
MWN-AI** Summary
Biotricity Inc. (OTCQB: BTCY) reported strong financial results for its third quarter of fiscal 2026, marking a significant growth trajectory in revenue and operational efficiency. The company's revenue climbed 10.2% to $4 million compared to $3.6 million in the previous year, driven by a robust adoption of its remote cardiac monitoring technologies. Buoyed by a 91.2% contribution from recurring Technology-as-a-Service (TaaS) fees, Biotricity's gross margin improved to 81.5%, up from 76.4% in the same quarter last year. Notably, the company achieved its third consecutive quarter of positive EBITDA, alongside a net loss reduction to $1.1 million from $1.3 million.
CEO Dr. Waqaas Al-Siddiq emphasized the growing need for proactive chronic care management to address the anticipated rise in cardiovascular diseases, which could affect over 60% of the population in the coming decades. Biotricity’s solutions are designed to facilitate early intervention and improve patient outcomes while enhancing the operational capabilities of healthcare providers. The company has experienced high customer retention rates, with satisfaction levels exceeding 90%, reflecting the effectiveness of its diagnostic technologies and customer support.
Strategically, Biotricity has made advances in securing regulatory approvals in multiple international markets, positioning itself for further growth. The company is set to receive FDA clearance for its innovative AI clinical model shortly, leveraging extensive data from over two trillion anonymized heartbeats to enhance diagnostic accuracy and streamline operational processes. As Biotricity continues to expand its digital ecosystem, its commitment to improving healthcare delivery is expected to drive sustainable long-term growth, ultimately transforming the cardiac care landscape.
MWN-AI** Analysis
Biotricity Inc. (OTCQB: BTCY) has showcased a robust performance in its third quarter of fiscal 2026, underscoring its potential for sustainable growth in the rapidly expanding remote healthcare space. With a 10.2% revenue increase to $4 million and significant improvements in gross margins, Biotricity is capitalizing on the rising demand for proactive chronic care management solutions.
The company’s impressive gross margin of 81.5%, up from 76.4% year-over-year, highlights its operational efficiencies backed by AI technology. This efficient model not only enhances diagnostic accuracy but also allows for improved throughput, making Biotricity’s offerings increasingly appealing to healthcare providers. Their strategic focus on delivering high-quality remote cardiac monitoring has led to a commendable 90% customer retention rate, which is critical in maintaining a steady revenue stream and further growth.
Looking ahead, Biotricity’s forthcoming FDA clearance for their AI clinical model is a pivotal milestone that could significantly enhance their market position. With cardiovascular disease projected to affect over 60% of the population in the coming decades, the need for innovative solutions like those provided by Biotricity is palpable.
For investors, Biotricity represents a compelling opportunity to enter a sector poised for exponential growth. Given the company’s strong financial results and operational performance, as well as its strategic initiatives to expand both in national and international markets, Biotricity is well-positioned to capitalize on the urgent need for effective chronic condition monitoring solutions.
As the remote monitoring market continues to mature, investors should keep an eye on Biotricity’s ability to leverage its existing technology and customer base to gain competitive advantages. Given the firm’s track record and growth potential, it may be prudent to consider Biotricity as a viable addition to a diversified investment portfolio focused on healthcare technology.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency.
Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, “The need for proactive chronic care management has never been greater. We’re proud to deliver our third consecutive quarter of positive EBITDA and net operating income, which reflects continued revenue growth, sustained margins, and disciplined operational execution. Over the next 30 years, cardiovascular disease is projected to impact over 60% of the population. This represents nearly $1.8 trillion in costs, even though up to 80% of cases are preventable with early intervention. We believe this underscores the urgent need to shift care from reactive treatment to proactive monitoring.
Biotricity is helping lead that transition by bringing clinical-grade, easy-to-use diagnostic solutions out of episodic care settings and into everyday life, where most meaningful health events occur. Our approach allows providers to extend care beyond traditional touchpoints so they can serve more patients and improve outcomes without adding additional workload. The strength of this model is reflected in our rapidly expanding digital ecosystem and high customer retention of 90+%. In just 2 years our app base has scaled from 4,500 to more than 44,000 users, and our network of over 2,500 providers that support 4,000,000 patients annually continues to grow.
Importantly, we’re on track to obtain FDA clearance for our groundbreaking AI clinical model in the coming months. Our Cardiac AI Cloud platform leverages more than two trillion anonymized heartbeats to enhance diagnostic accuracy, improving throughput. Combined with our automation and operational AI capabilities, our technologies enable us to scale efficiently and pass those efficiencies on to our customers. The result is higher-quality care, more patients served, and increased revenue opportunities for medical facilities, creating meaningful value across the care continuum with both providers and patients winning. By facilitating this, Biotricity is positioned for sustainable, long-term growth as customer satisfaction drives adoption and expansion, allowing us to continue to revolutionize the cardiac care landscape.”
Q3-FY26 Financial Highlights
- Revenue increased 10.2% to $4 million from $3.6 million in the corresponding prior year period
- Gross margin was 81.5% for the three months ended December 31, 2025, as compared to 76.4% in the corresponding prior year quarter; this is the result of expansion in the recurring technology fee revenue base, efficiencies gained using proprietary AI in operational automation, and improvement in monitoring and cloud cost structure.
- Net loss decreased to $1.1 million, or $0.042 per share, from a net loss of $1.3 million, or $0.054 per share; this was a 13% improvement from the corresponding prior year quarter.
Operating Highlights for Q3-FY26 and the Future
- Q3-FY26 recurring (TaaS) Technology Fees rose a robust 7.4% from the corresponding prior year period to $3.6 million, representing 91.2% of total revenue for Q3-FY26
- The Company maintained its track record of strong customer retention, supported by the quality of its solutions, best-in-class customer support, and accuracy and ease-of-use of its diagnostic technology.
- With approvals in Canada, Saudi Arabia, and Argentina, the Company continued to advance strategic regulatory approvals across international markets, laying the foundation for distribution partnerships.
- Leveraging its seasoned sales force and strategic partnerships, the Company continued to expand its footprint across broader national markets, with penetration across thousands of cardiologists in hundreds of centers.
Full details of the Company's financial results will be filed with the SEC on Form 10-K and available by visiting www.sec.gov.
Financial Results and Business Update Conference Call
Management will host a conference call on Wednesday, February 11th, 2026 at 4:30 p.m. ET to discuss its financial results for fiscal third quarter of 2026 and provide a business update. Additional details are available under the Investor Relations section of the Company's website: https://www.biotricity.com/investors/
Event: Biotricity Fiscal 2026 Third Quarter Financial Results and Business Update Call
Date: Wednesday February 11th, 2026
Time: 4:30pm ET (1:30pm PT)
Toll Free: 1-877-269-7751
International: 1-201-389-0908
Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1751341&tp_key=10b4deecf5
Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.
A replay of the call will be available approximately three hours after the live call via the Investors section of the Biotricity website at https://www.biotricity.com/investors/.
Toll Free Replay Number: 1-844-512-2921
International: 1-412-317-6671
Replay Access ID: 13758520
Expiration: Wednesday February 25, 2026 at 11:59 PM ET
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
To learn more about the benefits of using Biotricity’s solutions, click here and here. For consumers interested in continuous, 24/7 clinical-grade monitoring at home with Bioheart, click here.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of any of the Company's products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts
Investor Relations
Biotricity Investor Relations
Investors@biotricity.com
SOURCE: Biotricity, Inc.
Media
Website
Facebook
Instagram
LinkedIn
YouTube
FAQ**
How does Biotricity Inc. (BTCY) plan to sustain its revenue growth trajectory while expanding its digital ecosystem in the competitive landscape of remote cardiac monitoring?
What specific strategies are in place for Biotricity Inc. (BTCY) to increase its customer retention rate beyond the current 90% as competition intensifies in the healthcare technology sector?
Given Biotricity Inc. (BTCY)'s focus on proactive care management, how will the anticipated FDA clearance for the AI clinical model impact its market position and revenue potential?
What are the key challenges Biotricity Inc. (BTCY) foresees in securing further international regulatory approvals to enhance its global market presence in remote patient monitoring?
**MWN-AI FAQ is based on asking OpenAI questions about Biotricity Inc. (OTC: BTCY).
NASDAQ: BTCY
BTCY Trading
15.73% G/L:
$0.2546 Last:
1,765 Volume:
$0.241076 Open:
